-
公开(公告)号：US20240350531A1
公开(公告)日：2024-10-24
申请号：US18684909
申请日：2022-08-18
申请人： ARC Medical Inc.
IPC分类号： A61K31/737 , A61P19/04 , A61P37/06
CPC分类号： A61K31/737 , A61P19/04 , A61P37/06
摘要： Compositions and methods comprising medically-acceptable fucans suitable for medical and surgical applications, including treatment of capsular contracture and other foreign body reaction (FBR) conditions, and medical and surgical applications related to transplants and transplant operations, such as GVHD and fibrous growth around or on implants or transplants after implantation/transplantation, and related diseases, infections, and traumas.
-
公开(公告)号：US20240342208A1
公开(公告)日：2024-10-17
申请号：US18750691
申请日：2024-06-21
发明人： Thomas Michael VAUGHN , Joshua Alan HARRISON , Karl F. POPP , David J. FAIRFAX , Thomas Edward D'AMBRA , John QUINN
CPC分类号： A61K31/737 , A61K9/0014 , A61K9/06 , A61K45/06 , A61P19/02 , A61P29/00
摘要： One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.
-
3.发明公开公开(公告)号：US20240285674A1
公开(公告)日：2024-08-29
申请号：US18577953
申请日：2022-07-04
发明人： Jianfa ZHANG , Qian LIN , Lei WANG
IPC分类号： A61K31/737 , A61P7/02 , C08B37/00
CPC分类号： A61K31/737 , A61P7/02 , C08B37/006
摘要： The present invention relates to the field of anticoagulant and antithrombotic drugs, and in particular to an application of sulfate gluco-galacto-oligosaccharide in preparation of an anticoagulant and/or antithrombotic drug. Disclosed in the present invention is the application of sulfate gluco-galacto-oligosaccharide in the preparation of the anticoagulant and/or antithrombotic drug. The structural formula of sulfate gluco-galacto-oligosaccharide is that R1-R24 are independently SO3− or H, but not all H. Sulfate gluco-galacto-oligosaccharide of the present invention has obvious anticoagulant activity in vivo and in vitro, and can be used for preparing the anticoagulant and/or antithrombotic drug.
-
公开(公告)号：US20240099976A1
公开(公告)日：2024-03-28
申请号：US18490255
申请日：2023-10-19
IPC分类号： A61K9/127 , A61K8/04 , A61K8/14 , A61K9/00 , A61K9/10 , A61K31/155 , A61K31/165 , A61K31/355 , A61K31/522 , A61K31/60 , A61K31/618 , A61K31/7008 , A61K31/737 , A61K47/24 , A61K47/26 , A61P17/04 , A61P17/10 , A61Q19/00 , A61Q19/02 , A61Q19/08
CPC分类号： A61K9/1272 , A61K8/04 , A61K8/14 , A61K9/0014 , A61K9/10 , A61K9/127 , A61K31/155 , A61K31/165 , A61K31/355 , A61K31/522 , A61K31/60 , A61K31/618 , A61K31/7008 , A61K31/737 , A61K47/24 , A61K47/26 , A61P17/04 , A61P17/10 , A61Q19/00 , A61Q19/02 , A61Q19/08 , A61K33/30
摘要： The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.
-
公开(公告)号：US20240082296A1
公开(公告)日：2024-03-14
申请号：US18246569
申请日：2021-10-07
申请人： TX MEDIC AB
发明人： Lars BRUCE
IPC分类号： A61K31/737 , A61P21/00 , A61P25/28
CPC分类号： A61K31/737 , A61P21/00 , A61P25/28
摘要： The present invention relates to the use of dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment or prevention of muscle atrophy in a subject suffering from sarcopenia and in improving muscle function in a subject suffering from a neuromuscular disease and/or damage or sarcopenia.
-
公开(公告)号：US20240033282A1
公开(公告)日：2024-02-01
申请号：US18256926
申请日：2021-11-05
发明人： Gultekin TAMGUNEY
IPC分类号： A61K31/727 , G01N33/50 , A61K31/737 , A61P25/28
CPC分类号： A61K31/727 , G01N33/5058 , G01N33/5038 , A61K31/737 , A61P25/28
摘要： A method for identifying and/or for obtaining active substances for the alleviation or treatment of ALS includes: a. providing a composition containing cells having the cell surface receptors syndecan-3 and/or syndecan-1, b. contacting the composition from step a) with SOD1 aggregates, c. contacting the composition from step a) with the test substance to be screened, it being possible for step b) and step c) to be performed simultaneously or for step c) to be performed before step b), and d. determining the uptake of the SOD1 aggregates into the cells, and a kit for carrying out the method, are provided. Medicaments comprising pentosan polysulfate sodium (PPS) or compounds from the group of heparins or heparin-like compounds, and methods of using the same, are also provided.
-
公开(公告)号：US20230346828A1
公开(公告)日：2023-11-02
申请号：US18112106
申请日：2023-02-21
发明人： Doron Friedman
IPC分类号： A61K31/737 , A61P29/00 , A61K9/48 , A61K31/404 , A61K31/573 , A61K36/02
CPC分类号： A61K31/737 , A61P29/00 , A61K9/48 , A61K31/404 , A61K31/573 , A61K36/02
摘要： The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.
-
公开(公告)号：US11752169B2
公开(公告)日：2023-09-12
申请号：US17284071
申请日：2019-10-10
发明人： Paul Rennie , Ravi Krishnan
IPC分类号： A61K31/737 , A61P19/02 , A61P25/04 , A61K31/7032 , A61K31/727
CPC分类号： A61K31/737 , A61K31/7032 , A61K31/727 , A61P19/02 , A61P25/04
摘要： The present disclosure relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of pain or pain conditions. In particular, the disclosure relates to use of polysulfated polysaccharides and compositions thereof for the treatment of pain or pain conditions mediated by mature Nerve Growth Factor (NGF) or its precursor pro-Nerve Growth Factor (pro-NGF).
-
公开(公告)号：US20230270802A1
公开(公告)日：2023-08-31
申请号：US18002665
申请日：2021-06-28
IPC分类号： A61K36/03 , A61K31/737 , A61K9/08 , A61K9/00 , A61P31/14
CPC分类号： A61K36/03 , A61K9/08 , A61K9/0043 , A61K31/737 , A61P31/14
摘要： Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of coronavirus infection in a human. Particularly, the viral infection is OC43 or SARS-CoV-1 or SARS-CoV-2 infection. There are also described Pharmaceutical compositions comprising fucoidan for use in a method for prevention coronavirus spread in a human population, wherein subjects of the population are tested for infection with OC43 or SARS-CoV-1 or SARS-CoV-2 and infected subjects are treated with intranasal administration of the Pharmaceutical composition.
-
公开(公告)号：US20230263822A1
公开(公告)日：2023-08-24
申请号：US18150381
申请日：2023-01-05
发明人： Susan M. Freier , Chenguang Zhao , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Andrew M. Siwkowski
IPC分类号： A61K31/7125 , C07H21/00 , C12N15/113 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/737 , A61K31/727
CPC分类号： A61K31/7125 , C07H21/00 , C12Y304/21027 , C12N15/1137 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/737 , A61K31/727 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346
摘要： Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
-
-
-
-
-
-
-
-
-
搜索结果
1114 条记录 (耗时 0.025 秒)
